Epix Pharmaceuticals, Inc.
7
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
42.9%
3 terminated/withdrawn out of 7 trials
57.1%
-29.4% vs industry average
14%
1 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
Role: lead
A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
Role: lead
Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease
Role: lead
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
Role: lead
A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)
Role: lead
Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept
Role: lead
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
Role: lead
All 7 trials loaded